No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients

Documenti analoghi

• Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients
  di: Yoshimura, Reiji, et al.
  Pubblicazione: (2014)
• COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study
  di: Hayashi, Kenji, et al.
  Pubblicazione: (2014)
• Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs
  di: Yoshimura, Reiji, et al.
  Pubblicazione: (2014)
• Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder
  di: Atake, Kiyokazu, et al.
  Pubblicazione: (2014)
• Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder
  di: Yoshimura, Reiji, et al.
  Pubblicazione: (2014)